Compare ResMed Inc. (RMD) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Zillow Group Inc Class C — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Zillow Group Inc Class C trades at $32.17 (market cap $7.31B). The key difference: ResMed Inc. is far larger — about 4.4× Zillow Group Inc Class C's market cap, and ResMed Inc. pays a 1.19% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.
| RMD | Z | |
|---|---|---|
Market Cap | $31.89B | $7.31B |
Sector | Health | Media |
52-Week High | $283.28 | $90.35 |
52-Week Low | $182.82 | $29.41 |
Enterprise Value | $31.24B | $7.19B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Zillow Group (Z) trades at $32.36, down 6.45% amid a challenging housing market. The stock shows bearish technical signals with support at $30 and resistance at $34. Fundamentally, revenue growth continues (2025: $2.58B, 2026: $2.8B projected) with improving profitability (net margin turning positive at 1.96% in 2025). Recent Q2 2026 earnings beat expectations with $0.52 EPS versus $0.4459 expected, though the company faces regulatory scrutiny from a recent FTC settlement.
Despite near-term headwinds, Zillow's transition to an integrated transaction platform and strong rental market presence offer long-term growth potential. Key risks include housing market volatility, competitive pressures, and ongoing legal challenges. Analyst consensus price target of $52 suggests significant upside potential from current levels, though technical indicators remain bearish in the short term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
